Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Earnings for Satsuma Pharmaceuticals, Inc. (STSA)
Earnings in 2022 (TTM): $-70,055,000
According to Satsuma Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-70,055,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Satsuma Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-70,055,000 | $-69,163,000 |
| 2021 | $-51,172,000 | $-51,264,000 |
| 2020 | $-47,563,000 | $-47,674,000 |
| 2019 | $-28,175,000 | $-28,515,000 |
| 2018 | $-7,346,000 | $-7,346,000 |
| 2017 | $-5,172,000 | $-5,172,000 |